BioViva

BioViva is a biotechnology company dedicated to developing gene therapies designed to slow, stop, or reverse the biological aging process. The company is best known for its pioneering work in telomere lengthening and muscle mass enhancement, famously initiated through self-experimentation by CEO Elizabeth Parrish. BioViva's research focuses on utilizing viral vectors, including a proprietary cytomegalovirus (CMV) platform, to deliver therapeutic genes such as TERT and Follistatin. By targeting the fundamental mechanisms of cellular aging, the company aims to treat a variety of age-related conditions, including Alzheimer's disease and sarcopenia. BioViva operates primarily in the pre-clinical and early clinical stages, often collaborating with international partners to facilitate human trials outside of traditional regulatory jurisdictions.